Tresiba What to Expect: A Week-by-Week Guide to Your First Month

Why the First Month Matters More Than Any Other Period

The first 30 days on insulin degludec set the trajectory for long-term glycemic control. Patients who titrate too cautiously stay hyperglycemic longer than necessary; those who titrate too aggressively accumulate insulin before steady state is reached and face stacking risk. Getting the first month right requires understanding the pharmacokinetics before touching the dose dial.

The Pharmacokinetics That Drive Your Timeline

Insulin degludec forms soluble multi-hexamer chains at the subcutaneous injection site. These chains dissipate slowly, releasing monomers into the bloodstream over more than 42 hours. The FDA label confirms a half-life of approximately 25 hours and steady-state achievement after 2 to 3 days of once-daily dosing. [1]

Because of that prolonged half-life, a dose change made on Monday will not show its full glucose-lowering effect until Thursday or Friday. Patients who adjust doses daily based on single fasting readings will consistently overshoot or undershoot. The American Diabetes Association's 2024 Standards of Care explicitly recommend waiting at least 3 days between basal insulin titration steps. [2]

How Degludec Differs From Glargine and Detemir

Glargine U-100 has a half-life of roughly 12 hours and reaches steady state faster, typically within 1 to 2 days. [3] Detemir has a half-life of 5 to 7 hours and is often dosed twice daily. Degludec's 25-hour half-life produces a flatter, more predictable pharmacodynamic profile with a coefficient of variation for glucose-lowering effect of approximately 20%, compared to roughly 82% for NPH. [4] That lower variability is why week-to-week glucose patterns on degludec tend to be more consistent once titration is complete.

Week 1: Starting Dose, Injection Technique, and What You Will Actually Feel

Most patients notice little dramatic change in the first seven days. That is expected, not a sign the medication is failing.

Starting Doses by Clinical Scenario

For insulin-naive type 2 patients, the standard starting dose is 10 units subcutaneously once daily, or 0.1 to 0.2 units/kg once daily, per the FDA-approved prescribing information. [1] Patients converting from once-daily basal insulin (glargine or detemir) typically start at a 1:1 unit conversion. Patients converting from twice-daily NPH or detemir should reduce the total daily dose by 20% to account for degludec's greater potency per unit at steady state. [5]

Injection Sites and Rotation

Subcutaneous injection into the abdomen, thigh, or upper arm are all acceptable. Consistent rotation within one region reduces lipohypertrophy, which can reduce insulin absorption by up to 25% in affected tissue. [6] Choose a time of day that fits your routine. The flexible dosing window studied in BEGIN Flex (N=687) confirmed that varying injection timing by up to 40 hours between doses did not significantly increase hypoglycemia or worsen HbA1c compared to fixed-time daily dosing. [7]

Symptoms to Expect in Week 1

Patients occasionally report mild injection-site reactions, including redness or swelling lasting less than 24 hours. Systemic hypersensitivity is rare. Blood glucose readings in week 1 may actually rise slightly if a patient was previously on a higher-dose basal with a shorter half-life, then converted at a 20% reduction. That is not a warning sign. It reflects the dose reduction, not drug failure.

Week 2: Approaching Steady State and the First Titration Decision

By day 3 to 4, plasma degludec concentrations are at steady state. Week 2 is when fasting glucose trends become meaningful and the first dose adjustment decision should be made.

Reading Your Fasting Glucose Log

Fasting plasma glucose, measured on waking before any food or short-acting insulin, is the primary titration signal for basal insulin. The ADA 2024 Standards of Care set a fasting glucose target of 80 to 130 mg/dL for most non-pregnant adults with type 2 diabetes. [2] For type 1 patients, the target is typically 80 to 130 mg/dL as well, though individual clinical targets vary. [2]

Applying the 3-Day Rule

The most widely validated titration algorithm for once-daily basal insulin calls for increasing the dose by 2 units if the average fasting glucose over 3 consecutive days exceeds 110 mg/dL. [8] Some clinicians prefer the Treat-to-Target algorithm from the BEGIN trials, which used a similar 2-unit increment every 3 days with a fasting target of 71 to 90 mg/dL for the intensive arm. [9]

If any fasting reading falls below 72 mg/dL, hold the dose increase and reduce by 2 to 4 units. If a confirmed fasting glucose falls below 56 mg/dL, reduce the dose by 10% regardless of where the 3-day average stands.

What Week 2 Glucose Graphs Typically Look Like

Expect a gradual, stepwise decline in fasting glucose across week 2 as the drug accumulates. Postprandial glucose control depends on prandial insulin coverage and is not primarily a degludec effect. Patients sometimes confuse a flat fasting glucose trend with postprandial excursions and conclude the basal insulin is not working. These are separate problems requiring separate solutions.

Week 3: Optimizing the Dose and Managing Hypoglycemia Risk

Week 3 is when hypoglycemia risk tends to peak for patients who have been titrating aggressively. Degludec's long half-life means that an overshoot from week 2 titration continues to exert glucose-lowering pressure through the middle of week 3.

Nocturnal Hypoglycemia: What the DEVOTE Data Show

The DEVOTE trial (N=7,637, mean follow-up 2 years) compared insulin degludec to insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk. Degludec produced a 27% lower rate of severe nocturnal hypoglycemic episodes compared to glargine U-100 (rate ratio 0.73, 95% CI 0.60 to 0.89, P<0.001). [10] Severe hypoglycemia was defined as an episode requiring the assistance of another person.

The nocturnal advantage is particularly relevant in weeks 3 and 4, when cumulative dose adjustments raise the risk of overnight lows. Patients and caregivers should be counseled to check bedtime glucose before sleep and to have 15 grams of fast-acting carbohydrate available. The "15-15 rule" (15 g carbohydrate, recheck in 15 minutes) remains the standard ADA-endorsed treatment for mild-to-moderate hypoglycemia. [2]

Recognizing Stacking Before It Happens

Dose stacking with degludec is subtle because the glucose-lowering effect of a new increment adds onto the existing pharmacodynamic plateau rather than producing a sharp drop. Early signs of impending hypoglycemia include fasting readings trending below 90 mg/dL on two consecutive days. Pause titration and hold the current dose for at least 6 days before reassessing. Do not reduce unless a reading actually drops below 72 mg/dL.

Concomitant Medications That Affect Hypoglycemia Risk

Sulfonylureas, meglitinides, and alcohol each independently lower glucose and compound degludec's hypoglycemia risk in week 3. [11] Beta-blockers may mask tachycardia, one of the early autonomic warning signs, without blocking diaphoresis. Patients on non-selective beta-blockers need specific counseling about this interaction. [12] ACE inhibitors and angiotensin-receptor blockers may enhance insulin sensitivity and require monitoring, particularly during the titration weeks. [13]

Week 4: Assessing Glycemic Control and Planning Ahead

By the end of week 4, a reliable picture of the drug's basal effect is available. HbA1c will not have changed meaningfully yet, since the glycated hemoglobin reflects approximately 3 months of average glucose. However, fasting glucose trends, hypoglycemia frequency, and time-in-range (if the patient uses continuous glucose monitoring) provide actionable information.

What a Successful Month Looks Like

A patient who started at 10 units and titrated correctly may be at 18 to 24 units by day 28, with fasting glucose readings consistently in the 90 to 120 mg/dL range. No severe hypoglycemic episodes should have occurred. Mild nocturnal readings below 70 mg/dL that resolved with carbohydrate intake are acceptable, though they suggest the titration ceiling has been approached.

Time-in-Range as a Supplementary Endpoint

For patients using continuous glucose monitoring, the ADA recommends targeting greater than 70% time-in-range (70 to 180 mg/dL) in most adults with type 2 diabetes. [2] A 2021 analysis published in Diabetes Care found that each 10% increase in time-in-range corresponded to approximately a 0.8% reduction in HbA1c. [14] After 4 weeks on degludec, CGM users should expect improving overnight time-in-range as the primary early signal of basal adequacy.

Situations That May Require Faster Titration

Patients with fasting glucose values consistently above 200 mg/dL at week 4 likely have significant insulin resistance and may need 4-unit increments every 3 days rather than 2-unit increments. [15] A body weight greater than 100 kg is a common clinical trigger for this approach. An endocrinology or diabetes specialist referral is appropriate if total daily basal insulin exceeds 0.5 units/kg without reaching fasting glucose target.

Cardiovascular Safety: The DEVOTE Trial in Depth

Primary Cardiovascular Outcome

DEVOTE enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk and randomized them to degludec or glargine U-100, both titrated to a fasting glucose target of 71 to 90 mg/dL. The primary endpoint was time to first major adverse cardiovascular event (MACE: CV death, non-fatal MI, or non-fatal stroke). [10]

Degludec achieved non-inferiority to glargine on MACE (hazard ratio 0.91, 95% CI 0.78 to 1.06). The absolute MACE rates were 8.5% for degludec and 9.3% for glargine over approximately 2 years. Published in the New England Journal of Medicine in 2017, DEVOTE was the cardiovascular outcomes trial required by the FDA for new antidiabetic agents under the 2008 guidance. [10]

Hypoglycemia Sub-Analysis

The DEVOTE investigators performed a pre-specified analysis of severe hypoglycemia. Degludec produced 0.83 severe hypoglycemic episodes per patient-year versus 1.21 for glargine (rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001 for all severe hypoglycemia). [10] The nocturnal-specific rate ratio was 0.73, as noted above.

Severe hypoglycemia was itself independently associated with subsequent MACE in DEVOTE, a finding that underscores the clinical relevance of the nocturnal hypoglycemia advantage. [16] Avoiding hypoglycemia is not merely a comfort issue; the cardiovascular implications are measurable.

Dosing Flexibility: The Flexible Dosing Window

The BEGIN Flex trial (N=687) demonstrated that dosing insulin degludec at varying times each day, with injections separated by as few as 8 hours or as many as 40 hours, did not significantly increase hypoglycemia or worsen HbA1c at 26 weeks compared to fixed-time daily dosing. [7]

This flexibility is clinically meaningful. Patients with shift work, irregular meal schedules, or frequent travel across time zones may find that degludec's flexible window reduces the burden of rigid daily timing. Glargine requires a fixed daily time window for consistent dosing, making degludec a reasonable alternative in these populations. [17]

Special Populations

Type 1 Diabetes

The BEGIN Basal-Bolus Type 1 trial (N=629) demonstrated that degludec plus insulin aspart provided non-inferior HbA1c reduction compared to glargine plus aspart (change from baseline: degludec -0.40% vs. Glargine -0.39%), with a 25% lower rate of confirmed nocturnal hypoglycemia in the degludec arm. [18] Titration in type 1 patients generally starts lower (0.1 to 0.2 units/kg) and proceeds more cautiously given greater sensitivity. [5]

Renal Impairment

Insulin requirements may decrease as kidney function declines because the kidney contributes to insulin clearance. The degludec FDA label recommends intensified glucose monitoring in patients with renal impairment; no specific dose reduction formula exists, so clinical titration guided by fasting glucose remains the standard approach. [1]

Elderly Patients

Adults aged 65 and older are at increased risk of hypoglycemia due to reduced counterregulatory hormone responses, irregular meal intake, and polypharmacy. The DEVOTE sub-analysis confirmed that the nocturnal hypoglycemia advantage of degludec over glargine was maintained in patients aged 65 and older. [16] Starting doses should be at the lower end (6 to 8 units once daily) with 1-unit increments preferred.

Comparing Degludec to Other Basal Insulins: A Direct View

Degludec vs. Glargine U-300

Glargine U-300 (Toujeo) also has a longer duration of action than glargine U-100, with a half-life of approximately 19 hours and a duration exceeding 36 hours. A 2019 meta-analysis in Diabetes Care (N=6,906 pooled from EDITION and BRIGHT trials) found comparable HbA1c reduction between degludec and glargine U-300, with modestly lower hypoglycemia rates favoring degludec in some sub-analyses. [19] The choice between the two often comes down to payer formulary and pen device preference.

Degludec vs. NPH

NPH insulin has a peak effect at 4 to 8 hours and a duration of 12 to 18 hours, producing more hypoglycemia and greater glucose variability than any long-acting analog. [4] For patients switching from NPH to degludec, the starting dose is typically 60 to 80% of the total daily NPH dose to prevent hypoglycemia from the improved bioavailability of the analog formulation. [5]

Monitoring and Labs: A 30-Day Checklist

Structured monitoring during the first month reduces both hypoglycemia risk and unnecessary clinic calls. The following framework reflects ADA 2024 guidance and the BEGIN trial titration protocols. [2, 9]

• Days 1 to 3: Check fasting glucose daily. Establish baseline. Do not adjust dose.
• Days 4 to 6: If 3-day average fasting glucose exceeds 110 mg/dL, increase by 2 units. If any reading falls below 72 mg/dL, hold and reassess.
• Days 7 to 13: Continue 3-day titration cycle. Log every fasting reading. Report any reading below 56 mg/dL to the prescribing clinician same day.
• Days 14 to 20: Assess nocturnal readings if using CGM. A pattern of readings below 70 mg/dL between 2 a.m. And 6 a.m. Warrants a 10% dose reduction.
• Days 21 to 30: Evaluate fasting glucose trend, hypoglycemia frequency, and CGM time-in-range. Schedule follow-up HbA1c no earlier than 8 weeks after starting to capture a meaningful change signal.

Drug Interactions and Storage

Degludec should be stored in a refrigerator (36 to 46 degrees Fahrenheit) before first use. After first use, the pen may be kept at room temperature (59 to 86 degrees Fahrenheit) for up to 56 days. [1] Do not freeze. Do not use if the solution appears cloudy or contains particles.

Thiazolidinediones (pioglitazone, rosiglitazone) can cause fluid retention and increase the risk of heart failure when combined with any insulin; the FDA label includes a warning specific to this combination. [1] GLP-1 receptor agonists added to basal insulin regimens can allow a reduction in the basal insulin dose by 10 to 20% at initiation to prevent hypoglycemia. [20] Beta-blockers, as noted, may blunt sympathetic hypoglycemia warning signs without blocking diaphoresis. [12]